Immune checkpoint inhibitors show setting specific benefit in ovarian cancer meta analysis of 17 randomised trials

Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer

Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS

ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas

Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC

Highlights from APCCC 2026

ASCO 2026: Updates in bladder cancer

ASCO 2026: Updates in renal cancer

ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer

Favezelimab plus pembrolizumab improves progression-free survival in PD-1-refractory classic Hodgkin lymphoma

Metronomic chemo plus nivolumab (TMC-I) improves survival in R/M head & neck cancer vs platinum chemotherapy

ASCO 2026: Comment: Multi-cancer earlier detection tests